Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Pipeline Review Analyzing Therapeutic Development, H2 2017


Published on : Aug 08, 2017

Albany, New York, August 8, 2017: Leptin receptor is a human body protein that helps in easy access to various metabolic activities in the body. The downfall of this protein affects the human body and to stabilize, the various therapeutic developments are accomplished. To detail further, Market Research Hub (MRH) has recently added a pipeline review titled as “Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2017” to its vast report repository.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) acronym as LEP-R, a protein encoded by the LEPR gene that acts as a receptor for hormone LEP/leptin. The protein upon binding mediates LEP central and peripheral effects by activating different signaling pathways such as JAK2/STAT3 and MAPK cascade. The discussed protein is an appetite-regulating element, which induces a decrease in food intake and an increase in energy consumption. It also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. The pipeline report covers products from therapy areas such as metabolic disorders, central nervous system, and oncology which include indications for obesity, Alzheimer's disease, lipodystrophy, type 2 diabetes, and acquired generalized lipodystrophy (Lawrence Syndrome).

The report commences with the leptin receptor (HuB219 or OB Receptor or CD295 or LEPR) brief overview along with its therapeutic development, therapeutic assessment and companies involved in the development. The detailed development shows the products under development by stage of development, therapy area, indication and development by companies. It further showcases the therapeutic assessment and discusses the various assessment by the mechanism of action, route of administration and by molecule type. Moreover, the companies involved in the therapeutic development are also listed in the research that includes ConSynance Therapeutics Inc., Jyant Technologies Inc., NeuroNano Pharma Inc., Neurotez Inc., Novelion Therapeutics Inc. and XL-protein GmbH.

The consecutive section describes the various drugs profiled for the pipeline review, which covers drug profile, product description, the mechanism of action and the R&D progress. The drugs listed are CV-08, memtin, metreleptin, Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders, Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer, Recombinant Protein to Agonize Leptin Receptor for Obesity, Synthetic Peptide to Agonize Leptin Receptor for Metabolic Disorders and Alzheimer's disease, and XL-100. It further constitutes the leptin receptor (HuB219 or OB Receptor or CD295 or LEPR) dormant products, discontinued products, product development milestones and various featured news and press release. It helps in reliable assessment of the pipeline and hence gaining easy insight into the various drugs under the therapeutic development. 

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1256875

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top